Theralase Technologies Inc. V.TLT

Research Capital?

[livermore2]

Anyone know why they don't seem to cover theralase any longer. Haven't seen any recent write ups from Andre Uddin. Appreciate if anyone has any info on this as I believe RC was involved with the warrants expiring tomorrow.

[CancerSlayer]

It has been ~1 yr since Uddin's last client update.  In August 2023 he reported he was very bullish on Theralase & gave a "speculative buy" rating & a 1 year price target of $0.80, which equated to a 255% return at the time of publication (sp hovering in the $0.17-0.20 range at the time).  Well, we are far from that target, which may explain his silence.  To

[toade1313]

That will happen when the IF... and IF... and IF...  turn into WE DID.... and WE DID... and WE DID....

[CancerSlayer]

Yep...at least DIDs are always preceded by IFs ; ).  Keep the faith...our angel continues to hide in the details/data.  Imo, patience continues to be the prudent play despite it being frustratingly double-edged...unfortunately, drug R&D & its timelines are inherently unpredictable, which makes the vacillation of investing in biotech inescapable & all that more frustrating at

[riverrrow]

Research Capital was the brokerage involved in the LIFE financing for TLT  which failed miserably.

[james700]

Analysts are paid to have an opinion on stocks that their firm has financial ties with.  Analysts have a bias and don't always point you to where the real treasure is. IF the latest news turns out to be verified by further tests that Rutherin and Metformin combined prove to be a knock out punch to cancer. Then it's just a matter of time before this little Canadian biotech reaches a